Further, GFAP, which shows higher plasma levels in AD patients as in other neurodegenerative diseases (see Other plasma biomarkers), has resulted decreased in salivary samples with a decreasing trend as AD proceeds [ 193 ].
← all excerpts
Proteome-Based Biomarkers for Alzheimer's Disease: Old Acquisitions and Innovative Proposals.
1
—
—